Drilldown: Medicines
Medicines > classes 
:
Benzodiazepine or
Tryptamine or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]]
:
Benzodiazepine or
Tryptamine or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] Use the filters below to narrow your results.
generic:
brand:
None (35) ·
Avodart; combined with tamsulosin as Jalyn (1) ·
Cardura, Cardura XL (1) ·
Dalmane (1) ·
Doral (1) ·
Flomax (1) ·
Halcion (1) ·
Hytrin (US brand discontinued); mostly generic (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Onfi (1) ·
Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
None (48) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"' (1) ·
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
None (48) ·
0.25 mg (1) ·
0.4 mg PO once daily, 30 minutes after the same meal each day (1) ·
0.5 mg PO once daily (1) ·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
preparations:
None (48) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
0.4 mg capsules (1) ·
0.5 mg capsules (1) ·
1 mg, 5 mg tablets (1) ·
1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) ·
1, 2, 5, 10 mg capsules and tablets (1)
fda max:
onset:
None (48) ·
30-60 min (immediate-release); 1-2 h (extended-release) (1) ·
BP and symptomatic LUTS improvement within 1-2 weeks (2) ·
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) ·
Prostate volume reduction over 6-12 months (1) ·
Symptom improvement within 1 week; peak effect at 4-6 weeks (1)
duration:
halflife:
None (48) ·
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
9-15 hours'"`UNIQ--ref-000001BC-QINU`"' (1) ·
~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) ·
~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1) ·
~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"' (1) ·
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)
bioavailability:
None (48) ·
80-90% oral (1) ·
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1) ·
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' (1) ·
~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1)
pregnancy:
None (48) ·
'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not applicable (male indication); historical Category B if used in unrelated female cases.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 54 results in range #1 to #54.